125I episcleral plaque brachytherapy in the treatment of choroidal melanoma: A single-institution experience in Spain

Correa, Raquel; Pera, J.; Gómez, Joaquín; Polo, Alfredo; Gutiérrez, Cristina; Caminal, Josep M.; Modolell, Ignasi; Navarro, Valentı́; Guedea, Ferrán

doi:10.1016/j.brachy.2009.03.189

Cited by 26 publications

(11 citation statements)

References 21 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fourteen studies were retrospective clinical chart reviews [14,15,22,23,24,25,26,27,28,29,30,31,32], and 1 was a prospective, randomized trial, the COMS trial [17]. One retrospective study included patients from the COMS trial [15].…”

Section: Resultsmentioning

confidence: 99%

Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose

et al. 2017

View full text Add to dashboard Cite

Aim: To investigate whether lower radiation doses may yield similar outcome measures to those from the COMS trial. Methods: A literature review of English language articles was performed using the PubMed database of the U.S. National Library of Medicine and the Cochrane Central Register of Controlled Trials using the following keywords: uveal melanoma, choroidal melanoma, primary uveal malignant melanoma, iodine-125 brachytherapy, local recurrence, local treatment failure, and local tumor control. The relationships between study local recurrence rate and median dosage were tested by linear regression, with each study weighted by the number of patients included. Results: Fifteen retrospective and prospective studies were selected for systematic review (2,662 patients). Ranges of reported mean or median radiation dose to tumor apex were 62.5-104.0 Gy. Local recurrence rates ranged from 0 to 24%. A 1.0-Gy increase in the average study dose was associated with a 0.14% decrease in local recurrence rate, which was not statistically significant (p value 0.336). Conclusion: The gold standard empirically derived 85.0-Gy radiation dose for the treatment of uveal melanoma could be tested in a randomized study.

show abstract

Section: Resultsmentioning

confidence: 99%

Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose

et al. 2017

View full text Add to dashboard Cite

show abstract

“…These data were reflected in the 1999 update of the COMS manual of procedures, 17 which recommended a prescription dose of 85 Gy delivered at an average dose rate of 1.05-0.42 Gy/h. However, Quivey et al 18 found a significant (p < 0.0001) correlation between local control and overall treatment duration for 125 [20][21][22] but the current absence of a consensus implant duration or pertinent societal guidance restricts coordinated efforts toward correlating improved eye plaque brachytherapy dosimetry with toxicity, local control, and overall survival results.…”

Section: Ib Prescription Dose Implant Duration and Dose Ratementioning

confidence: 99%

Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function

2012

View full text Add to dashboard Cite

The results suggest that shorter implant durations may correlate with more favorable outcomes compared to 7 day implants when treating small or medium intraocular lesions. The data also indicate that implant duration may be safely reduced if the prescription physical dose is likewise diminished and that (103)Pd offers a substantial radiobiological benefit over (125)I and (131)Cs irrespective of plaque position, implant duration, and tumor size.

show abstract

“…However, the local control failure of COMS study was defined as the progression of the height of the tumor in 25%. When 125 I plaque therapy was applied, the rates of tumor controlling vary from 88.2-94% in diverse studies [5,6,7]. The 5-year local recurrence rate of CPT was around 5% [8,9,10].…”

Section: Discussionmentioning

confidence: 99%

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

Jiang

Purtskhvanidze

Kandzia

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To evaluate 106Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity.Methods: From 2007 to 2015, 39 patients were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the median tumor depth was 3.0 mm (CI: 1.6-8.9 mm). Median dose at the apex of the tumor was 145 Gy (± SD: 12.1Gy). The median sclera dose was 444.0Gy (±SD: 257.3 Gy). Results: Median follow-up was 61.5 months (CI: 8.1-138 mon.). 34 patients (87.1%) remained free of recurrence. In 26 (66.7%) patients a total regression was achieved after a median period of 12 months (CI: 3-60 mon.). By the final examination, the visual acuity of 26 (66.7%) patients was better than 20/200. 12 (30.7%) patients had a visual acuity better than 20/40.Retinopathy was detected in 11 (28.2%) patients. After treatments only 1 (5.1%) patients had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 (10.3%) patients. Cataract development was diagnosed in 21 (53.8%) patients, although 16 (41%) of them had bilateral cataract development.Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5mm or more. There was no significant difference neither in local control (75 % in tumors ≥5mm versus 92.6 % in tumors <5mm) nor in side effects between both groups. Conclusions: Our study proved 106 Ru -brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. The data suggest that this treatment is also suitable for tumors with a depth of more than 5mm.

show abstract

125I episcleral plaque brachytherapy in the treatment of choroidal melanoma: A single-institution experience in Spain

Cited by 26 publications

References 21 publications

Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose

Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose

Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function

106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma

Contact Info

Product

Resources

About